Core Viewpoint - The company has received approval for its recombinant type I α1 collagen freeze-dried fibers, marking a significant advancement in its medical aesthetics segment and enhancing its product portfolio [1] Group 1: Product Approval - The product "recombinant type I α1 collagen freeze-dried fibers" has been approved by NMPA on October 21, with registration number 20253132049, making it the first recombinant type I natural sequence collagen injection product in China [1] - The product is characterized as a white or off-white sponge-like solid composed of recombinant type I α1 collagen, utilizing a specific amino acid sequence of 753 amino acids [1] - It is indicated for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] Group 2: Financial Forecast - The company is projected to achieve net profits attributable to the parent company of 2.52 billion, 3.16 billion, and 3.81 billion yuan for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 22.2%, 25.3%, and 20.5% [2] - The recombinant collagen segment is expected to experience high growth potential, especially following the recent approval of the medical aesthetics product, which may provide significant marginal catalytic elasticity [2] - The company maintains a "buy" rating despite recent challenges faced by its cosmetics brand due to public opinion events [2]
巨子生物(02367.HK)：三类械成功获批 打开医美增长曲线